南方科技大学知识苑(SUSTech KC): Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma

题名	Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma
作者	Pan, Shida ; Yu, Yingying; Wang, Siyu ; Qiu, Qin ; Shen, Yingjuan ; Yang, Luo ; Liu, Xiaomeng ; Luan, Junqing ; Meng, Fanping
发表日期	2023-06-01
会议名称	PROCEEDINGS OF THE 2023 GENETIC AND EVOLUTIONARY COMPUTATION CONFERENCE, GECCO 2023
ISSN	0732-183X
EISSN	1527-7755
会议录名称	JOURNAL OF CLINICAL ONCOLOGY
卷号	41
期号	16
会议日期	2023
会议地点	Lisbon, PORTUGAL
出版地	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
出版者	LIPPINCOTT WILLIAMS & WILKINS
学校署名	其他
语种	英语
相关链接	[来源记录]
收录类别	SCI ; CPCI-S
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:001053772001700
ESI学科分类	CLINICAL MEDICINE
来源库	Web of Science
引用统计	被引频次[WOS]：0
成果类型	会议论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/571732
专题	南方科技大学医学院南方科技大学医学院_人类细胞生物和遗传学系
作者单位	1.Capital Med Univ, Beijing, Peoples R China 2.Southern Univ Sci & Technol, Sch Med, Dept Human Cell Biol & Genet, Shenzhen, Peoples R China 3.Fifth Med Ctr PLA Gen Hosp, Dept Infect Dis, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Pan, Shida,Yu, Yingying,Wang, Siyu,et al. Efficacy and safety of switching other tyrosine kinase inhibitors to regorafenib combined with primary PD-1 antibodies in patients with hepatocellular carcinoma[C]. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA:LIPPINCOTT WILLIAMS & WILKINS,2023.